William Plunkett
Affiliations: | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Pharmacology, Cell Biology, OncologyGoogle:
"William Plunkett"Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu X, Jiang Y, Nowak B, et al. (2020) Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination. Cancer Chemotherapy and Pharmacology |
| Banerjee P, Zhang R, Ivan C, et al. (2019) Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia. Cancer Immunology Research |
| Liu X, Jiang Y, Takata KI, et al. (2019) CNDAC-induced DNA double strand breaks cause aberrant mitosis prior to cell death. Molecular Cancer Therapeutics |
| Jain N, Keating M, Thompson P, et al. (2019) Ibrutinib and Venetoclax for First-Line Treatment of CLL. The New England Journal of Medicine. 380: 2095-2103 |
| Lai TH, Mitchell S, Wu PJ, et al. (2019) HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leukemia & Lymphoma. 1-4 |
| Chen R, Zhu M, Chaudhari RR, et al. (2019) Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia |
| Wierda WG, Lee ST, Chen R, et al. (2019) A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 134: 1761-1761 |
| Elsayed AH, Cao X, Crews KR, et al. (2018) Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics |
| Ravikrishnan J, Lai T, Mitchell SR, et al. (2018) Using HSP90 Inhibitors to Target DNA Repair Proteins in AML Blood. 132: 5144-5144 |
| Chen R, Chen Y, Frame S, et al. (2018) Abstract 3905: Strategic combination of the cyclin-dependent kinase inhibitor CYC065 with venetoclax to target anti-apoptotic proteins in chronic lymphocytic leukemia Cancer Research. 78: 3905-3905 |